LIM-Only Protein FHL2 Activates NF-κB Signaling in the Control of Liver Regeneration and Hepatocarcinogenesis

REFERENCES

• Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M. 2006. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci. 63:268–284.
   PubMedGoogle Scholar
• Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R. 2000. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 19:359–369.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I, Saito I, Saruta T. 2004. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr. Res. 30:617–621.
   PubMed Web of Science ®Google Scholar
• Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H, Lin J, Cheng L, Qin X, Niu C, Yuan B, Wang X, Zhu C, Zhou Y, Li J, Song H, Huang C, Ye Q. 2009. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J. Clin. Invest. 119:349–361.
   PubMedGoogle Scholar
• Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben-Ze'ev A, Medrano EE. 2003. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res. 63:6626–6634.
   PubMedGoogle Scholar
• Xia T, Levy L, Levillayer F, Jia B, Li G, Neuveut C, Buendia MA, Lan K, Wei Y. 2013. The four and a half LIM-only protein 2 (FHL2) activates transforming growth factor beta (TGF-beta) signaling by regulating ubiquitination of the E3 ligase Arkadia. J. Biol. Chem. 288:1785–1794.
   PubMedGoogle Scholar
• Morlon A, Sassone-Corsi P. 2003. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc. Natl. Acad. Sci. U. S. A. 100:3977–3982.
   PubMedGoogle Scholar
• Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M, Behrens J, von der Mark K, Starzinski-Powitz A, Wixler V. 2002. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J. Cell Biol. 159:113–122.
   PubMedGoogle Scholar
• Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA. 2003. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J. Biol. Chem. 278:5188–5194.
   PubMedGoogle Scholar
• Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y. 2004. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol. Cell. Biol. 24:10689–10702.
   PubMedGoogle Scholar
• Brun J, Fromigue O, Dieudonne FX, Marty C, Chen J, Dahan J, Wei Y, Marie PJ. 2012. The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b. Bone 53:6–12.
   PubMedGoogle Scholar
• Mille F, Thibert C, Fombonne J, Rama N, Guix C, Hayashi H, Corset V, Reed JC, Mehlen P. 2009. The patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat. Cell Biol. 11:739–746.
   PubMed Web of Science ®Google Scholar
• Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B, Novack DV, Ross FP, Teitelbaum SL. 2005. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 115:2742–2751.
   PubMedGoogle Scholar
• Hayden MS, Ghosh S. 2012. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26:203–234.
   PubMed Web of Science ®Google Scholar
• Smale ST. 2011. Hierarchies of NF-kappaB target-gene regulation. Nat. Immunol. 12:689–694.
   PubMed Web of Science ®Google Scholar
• Wong CH, Mak GW, Li MS, Tsui SK. 2012. The LIM-only protein FHL2 regulates interleukin-6 expression through p38 MAPK mediated NF-kappaB pathway in muscle cells. Cytokine 59:286–293.
   PubMedGoogle Scholar
• Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D. 2002. TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett. 521:165–169.
   PubMedGoogle Scholar
• Sun B, Karin M. 2008. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27:6228–6244.
   PubMed Web of Science ®Google Scholar
• Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:167–170.
   PubMed Web of Science ®Google Scholar
• Liu F, Xia Y, Parker AS, Verma IM. 2012. IKK biology. Immunol. Rev. 246:239–253.
   PubMed Web of Science ®Google Scholar
• Maeda S, Kamata H, Luo JL, Leffert H, Karin M. 2005. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977–990.
   PubMed Web of Science ®Google Scholar
• Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. 2007. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11:119–132.
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466.
   PubMed Web of Science ®Google Scholar
• Nouet Y, Dahan J, Labalette C, Levillayer F, Julien B, Jouvion G, Cairo S, Vives FL, Ribeiro A, Huerre M, Colnot S, Perret C, Nhieu JT, Tordjmann T, Buendia MA, Wei Y. 2012. The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis. J. Hepatol. 57:1029–1036.
   PubMedGoogle Scholar
• Chu PH, Bardwell WM, Gu Y, Ross JJr, Chen J. 2000. FHL2 (SLIM3) is not essential for cardiac development and function. Mol. Cell. Biol. 20:7460–7462.
   PubMedGoogle Scholar
• Nicou A, Serriere V, Prigent S, Boucherie S, Combettes L, Guillon G, Alonso G, Tordjmann T. 2003. Hypothalamic vasopressin release and hepatocyte Ca2+ signaling during liver regeneration: an interplay stimulating liver growth and bile flow. FASEB J. 17:1901–1903.
   PubMedGoogle Scholar
• Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F, Gendron MC, Renard CA, Regnault B, Chen J, Buendia MA, Wei Y. 2008. The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation. J. Biol. Chem. 283:15201–15208.
   PubMedGoogle Scholar
• Cougot D, Allemand E, Riviere L, Benhenda S, Duroure K, Levillayer F, Muchardt C, Buendia MA, Neuveut C. 2012. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci. Signal. 5: ra1.
   PubMedGoogle Scholar
• Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. 2002. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J. Immunol. 168:5989–5992.
   PubMed Web of Science ®Google Scholar
• Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F, Naveau S, Prevot S, Makhzami S, Perlemuter G, Cassard-Doulcier AM. 2012. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol. 57:141–149.
   PubMed Web of Science ®Google Scholar
• Taub R. 2004. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 5:836–847.
   PubMed Web of Science ®Google Scholar
• Fausto N, Laird AD, Webber EM. 1995. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J. 9:1527–1536.
   PubMed Web of Science ®Google Scholar
• Teramoto K, Bowers JL, Khettry U, Palombo JD, Clouse ME. 1993. A rat fatty liver transplant model. Transplantation 55:737–741.
   PubMedGoogle Scholar
• Weltman MD, Farrell GC, Liddle C. 1996. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645–1653.
   PubMed Web of Science ®Google Scholar
• Cornell RP, Liljequist BL, Bartizal KF. 1990. Depressed liver regeneration after partial hepatectomy of germ-free, athymic and lipopolysaccharide-resistant mice. Hepatology 11:916–922.
   PubMed Web of Science ®Google Scholar
• He G, Karin M. 2011. NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res. 21:159–168.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121–124.
   PubMed Web of Science ®Google Scholar
• He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. 2010. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17:286–297.
   PubMed Web of Science ®Google Scholar
• Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ. 2000. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351–361.
   PubMed Web of Science ®Google Scholar
• Chen ZJ. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7:758–765.
   PubMed Web of Science ®Google Scholar
• Hubbi ME, Gilkes DM, Baek JH, Semenza GL. 2012. Four-and-a-half LIM domain proteins inhibit transactivation by hypoxia-inducible factor 1. J. Biol. Chem. 287:6139–6149.
   Google Scholar
• Bai S, Zha J, Zhao H, Ross FP, Teitelbaum SL. 2008. Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts. J. Biol. Chem. 283:30861–30867.
   PubMedGoogle Scholar
• Qian Z, Mao L, Fernald AA, Yu H, Luo R, Jiang Y, Anastasi J, Valk PJ, Delwel R, Le Beau MM. 2009. Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo. Leukemia 23:1650–1657.
   PubMedGoogle Scholar
• Labalette C, Nouet Y, Levillayer F, Colnot S, Chen J, Claude V, Huerre M, Perret C, Buendia MA, Wei Y. 2010. Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice. PLoS One 5:e10371. doi:10.1371/journal.pone.0010371.
   PubMedGoogle Scholar